INTRODUCTION AND OBJECTIVES:
The opioid epidemic has been the recent focus of significant national initiatives to reduce the misuse of opioids and related addiction. Interstitial cystitis (IC) is a chronic pain state at risk for frequent narcotics use. Accordingly, we sought to assess narcotic prescription use in patients with IC through analysis of patient claims data.
METHODS: Data were accessed from the Virginia All Payers Claims Database (VAPCD), a dataset that includes medical and pharmacy claims from state residents insured through Medicare, Medicaid, and private commercial insurers. We identified female patients with diagnosis of IC from 2011-2017 using International Classification of Disease (ICD) codes 595.1 (ICD9) or N30.10 (ICD10). A patient identifier was used to link diagnosis claims with outpatient prescription claims for opioids by using generic product identifiers. We then analyzed opioid prescriptions within 30 days of a claim with IC diagnosis.
RESULTS: A total of 6,989 patients with an IC diagnosis were identified and were associated with 31,685 claims. Accordingly, the median number of IC claims per patients was 7 (IQR 3,21). Mean patient age was 48.6 (95% CI 48.5, 48.7). 27.8% of patients had at least 1 opioid prescription, with a median of 2 prescriptions (IQR 1, 4). In those patients receiving opioids. 186 (9.6%) patients had more than 10 prescriptions for opioids, with a max of 129. The most common prescriptions were hydrocodone (n[2579, 31.5%), oxycodone (n[1889, 23.1%), and tramadol (n[1139, 13.9%). In addition, prescriptions for methadone (n[101, 1.2%) and buprenorphine (n[40, 0.5%) were associated with IC diagnosis. Opioid prescriptions per month are shown in Figure 1 , demonstrating a decline in opioid prescriptions per month for IC. However, the rate of narcotic prescriptions per IC diagnosis remained stable.
CONCLUSIONS: A significant number of patients with IC diagnosis are treated with opioids, with a percentage receiving a large number of opioid prescriptions. While the overall number of opioid prescriptions associated with IC appears to be declining, the prescription rate per IC diagnosis has not declined over the study years. As part of the national initiative to reduce narcotics use, our data suggest that IC treatment strategies should be examined. METHODS: Using the Veterans Affairs Informatics and Computing Infrastructure (VINCI), we identified a random sample of patients with an ICD-9 diagnosis of IC/BPS and patients without an ICD-9 diagnosis of IC/BPS or other pelvic pain conditions by querying all living veterans in the VINCI system. Presence of eleven comorbidities was determined using ICD-9 diagnosis codes: Alcohol Abuse, Back Pain, Chronic Fatigue, Diabetes, Fibromyalgia, Irritable Bowel Syndrome, Migraines, Post-Traumatic Stress Disorder (PTSD), Sexual Trauma, Smoking and History of Depression. Differences between groups were tested using multivariable logistic regression where needed to adjust for age.
RESULTS: Data from 2,056 subjects were included in this analysis with 1,211 IC/BPS patients (538 males, 44% and 673 females, 56%) and 845 non-IC/BPS patients (424 males, 50% and 421 females, 50%). IC/BPS patients were more likely to be female (p[0.01) and were significantly older at the time of abstraction (p<0.0001). After adjusting for the significant difference of age, the predicted prevalence of most comorbidities was higher in IC/BPS subjects (Table 1) . For example, 41% of IC/BPS patients in our dataset were diagnosed with NUAS vs. 16% in non-IC/BPS patients. IC/BPS patients were nearly twice as likely to have a sexual trauma diagnosis (7% vs. 3%, p<.0001) and 1.4 times more likely to have a PTSD diagnosis (40% vs. 30%, p<.0001).
CONCLUSIONS: A significant percentage of IC/BPS patients were diagnosed with NUAS, which was consistent with the 47% found in a 2014 study by the MAPP Network (Krieger, et al.) . Our PTSD findings in 40% of IC/BPS patients supports the findings of one of the few studies to examine the relationship between PTSD and IC/BPS, which reported 42% prevalence (McKernan, et al.) . These data further elucidate the comorbidities associated with IC/BPS in male and female patients.
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